Calprotectin Test Predicts Relapse in RA and PsA

Feb 12, 2019

Calprotectin is a known marker of disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Now, researchers reporting in Arthritis Research and Therapy say that baseline calprotectin levels may predict disease relapse for RA and PsA patients on TNFi therapy. Learn more in this slideshow. 

Calprotectin is a known marker of disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Now, researchers reporting in Arthritis Research and Therapy say that baseline calprotectin levels may predict disease relapse for RA and PsA patients on TNFi therapy. Learn more in this slideshow.

References:

Jose Inciarte-Mundo, Julio Ramirez, Maria V Hernandez, et al. “Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study,” Arthritis Research & Therapy (2018) 20:275. https://doi.org/10.1186/s13075-018-1764-z